Leslie W Chinn (Leslie Chinn)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Replacement Therapy

Top Venues

CPT: pharmacometrics & systems pharmacology

Proceedings of the National Academy of Sciences of the United States of America

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology (2024)
Amos Baruch, Chin Wong, Leslie W Chinn, Anjali Vaze, Junichiro Sonoda, Thomas Gelzleichter, Shan Chen, Nicholas Lewin-Koh, Linda Morrow, Suresh Dheerendra, Richard Boismenu, Johnny Gutierrez, Eric Wakshull, Maria E Wilson, Puneet S Arora
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans. Proceedings of the National Academy of Sciences of the United States of America 117 (46) (2020)
Nicholas S Jones, Kenta Yoshida, Laurent Salphati, Jane R Kenny, Matthew R Durk, Leslie W Chinn
Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI. Clinical pharmacology and therapeutics 107 (1) (2019)